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This narrative review summarizes the role of vitamin C in mitigating oxidative injury-induced microcirculatory
impairment and associated organ failure in ischemia/reperfusion or sepsis. Preclinical studies show that high-dose
vitamin C can prevent or restore microcirculatory flow impairment by inhibiting activation of nicotinamide adenine
dinucleotide phosphate-oxidase and inducible nitric oxide synthase, augmenting tetrahydrobiopterin, preventing
uncoupling of oxidative phosphorylation, and decreasing the formation of superoxide and peroxynitrite, and by
directly scavenging superoxide. Vitamin C can additionally restore vascular responsiveness to vasoconstrictors,
preserve endothelial barrier by maintaining cyclic guanylate phosphatase and occludin phosphorylation and
preventing apoptosis. Finally, high-dose vitamin C can augment antibacterial defense. These protective effects
against overwhelming oxidative stress due to ischemia/reperfusion, sepsis or burn seems to mitigate organ injury
and dysfunction, and promote recovery after cardiac revascularization and in critically ill patients, in the latter
partially in combination with other antioxidants. Of note, several questions remain to be solved, including optimal
dose, timing and combination of vitamin C with other antioxidants. The combination obviously offers a synergistic
effect and seems reasonable during sustained critical illness. High-dose vitamin C, however, provides a cheap,
strong and multifaceted antioxidant, especially robust for resuscitation of the circulation. Vitamin C given as early as
possible after the injurious event, or before if feasible, seems most effective. The latter could be considered at the
start of cardiac surgery, organ transplant or major gastrointestinal surgery. Preoperative supplementation should
consider the inhibiting effect of vitamin C on ischemic preconditioning. In critically ill patients, future research should
focus on the use of short-term high-dose intravenous vitamin C as a resuscitation drug, to intervene as early as possible
in the oxidant cascade in order to optimize macrocirculation and microcirculation and limit cellular injury.Introduction
Critically ill patients suffer from multiple organ dysfunc-
tion mostly occurring in the course of ischemia/reperfu-
sion or septic shock. In these conditions, overwhelming
amounts of reactive oxygen species (ROS) and reactive
nitrogen species are generated. ROS are oxidizing agents
produced during mitochondrial respiration and phago-
cytosis. In addition, ROS cause post-translational modifi-
cations of proteins, modifying their action and affecting
cellular signaling, gene expression, oxygen sensing and
other physiological processes [1,2]. In low concentrations,
ROS also enhance the antioxidant response via nuclear
factor-erythroid 2-related factor 2 activation, and thereby
promote cell survival [2]. While ROS are crucial for body
homeostasis and defense, they cause harm if abundant pro-
duction overwhelms the antioxidant defense. In that case,
ROS can induce reversible or irreversible injury to proteins,* Correspondence: hmoudemans@gmail.com
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dysfunction, cellular injury and multiple organ dysfunction.
Endothelial dysfunction is a uniform, ROS-mediated
manifestation of ischemia/reperfusion and sepsis. Further-
more, ROS-induced damage to the glycocalyx, cellular
membranes and junctions leads to increased permeability,
adhesion of leukocytes and platelets with local activation of
inflammation and coagulation, leads to loss of endothelial
vasodilatation and attenuates the vascular response to vaso-
constrictors [3-6]. Subsequent hypotension, vascular leak-
age and microcirculatory flow impairment at reperfusion
augment tissue hypoxia due to increased diffusion distance
for oxygen and may thereby enhance cellular damage and
organ failure [7,8]. Ascorbate, the redox form of vitamin C,
is a physiological antioxidant. We hypothesize that the early
administration of a high pharmacological dose of vitamin
C to patients with sepsis or after ischemia/reperfusion can
reduce oxidative damage to endothelial and other cells, and
thereby improve tissue perfusion and oxygenation, and
mitigate subsequent organ dysfunction [9,10].BioMed Central. The licensee has exclusive rights to distribute this article, in any
n. After this time, the article is available under the terms of the Creative Commons
/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver
/1.0) applies to the data made available in this article, unless otherwise stated.
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immune function, and facilitates enteral uptake of non-
heme iron, reduction of folic acid intermediates and syn-
thesis of collagen (wound healing), cortisol, catecholamines
and carnitine [11-13]. These effects are beyond the scope
of this review.
The aim of this narrative review is to summarize the
role of vitamin C in mitigating ROS-induced damage to
endothelial and myocardial cells in ischemia/reperfusion
or sepsis. By limiting endothelial dysfunction, vitamin C
might improve tissue perfusion and reduce tissue hypoxia
and subsequent organ dysfunction. Experimental and
clinical studies on the use of vitamin C are reported with
a focus on cardiovascular effects.
Review
Pathophysiology
Ischemia/reperfusion-induced and sepsis-induced endo-
thelial dysfunction is initiated by increased amounts ofFigure 1 Ischemia/reperfusion-induced and sepsis-induced endothelial
species. 1. Ascorbate reduces the production of superoxide (O2
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signaling pathway, which leads to subunit p47phox expression of nicotinamid
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depletion and eNOS uncoupling. 3. Ascorbate inhibits inducible nitric oxide sy
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phosphatase 2A (PP2A) activation, which dephosphorylates occludin. Phosph
Ascorbate inhibits myocardial apoptosis by preventing Bax activation, which d
mitochondria into the cytoplasm and subsequent caspase-3 activation, which
Ascorbate inhibits microcirculatory flow impairment by inhibiting tumor necr
which triggers leukocyte stickiness and sludging. cAMP, cyclic adenosine mon
triphosphate; I/R, ischemia/reperfusion; sGC, soluble guanylate cyclase.ROS produced by the induction of enzymes such as nico-
tinamide adenine dinucleotide phosphate-oxidase (NOX)
and uncoupling of mitochondrial oxidative phosphoryl-
ation and endothelial nitric oxide synthase (eNOS). ROS
are additionally produced by xanthine oxidase, lipoxygen-
ase and cyclooxygenase, and during oxidation of catechol-
amines (Figure 1) [1,13].
Unopposed ROS oxidize tetrahydrobiopterin (BH4),
the cofactor of eNOS, and thereby reduce eNOS activity,
the enzyme producing endothelial nitric oxide (eNO).
eNO initiates vasodilatation by stimulating soluble guanyl-
cyclase and increasing cyclic guanosine monophosphate
in smooth muscle cells [14]. It also inhibits platelet aggre-
gation and adhesion of activated platelets and leukocytes.
eNO is therefore crucial for patency of the microcir-
culation and its depletion hampers organ perfusion and
oxygenation. In the absence of BH4, eNOS becomes
uncoupled, producing superoxide (O2
–) rather than nitric
oxide (NO) [15]. O2
– and NO yield peroxynitrite, the most
damaging ROS.dysfunction is initiated by increased amounts of reactive oxygen
eroxide and peroxynitrite (OONO–) by inhibiting the Jak2/Stat1/IRF1
e adenine dinucleotide phosphate oxidase (NADPH-ox) and thus to
ical vasoconstriction and loss of endothelial barrier by inhibiting
nthase (eNOS), thereby preventing endothelial nitric oxide (eNO)
nthase (iNOS) mRNA and iNOS expression, preventing abundant
. 4. Ascorbate protects against vascular leakage by inhibiting protein
orylated occludin is crucial for maintenance of tight junctions. 5.
ecreases the ability of BCl-2 to inhibit cytochrome-C release from the
initiates apoptosis. The combination with vitamin E is synergistic. 6.
osis factor-induced intracellular adhesion molecule (ICAM) expression,
ophosphate; cGMP, cyclic guanosine monophosphate; GTP, guanosine
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The underlying mechanisms for the effect of ascorbate
on these pathways have been demonstrated in in vitro
studies with cultured endothelial cells. Endothelial cells
can accumulate ascorbate to millimolar levels [16] and
represent an appropriate model to study the effects of
high-dose vitamin C. In vitro studies are presented fo-
cusing on protective effects of vitamin C (ascorbate)
in ischemia/reperfusion and sepsis.
Endothelial dysfunction
Ascorbate decreases oxidative stress in endothelial cells
by reducing the production of O2
–, hydrogen peroxide
and peroxynitrite. Mechanisms include prevention of
NOX activation, decreased inducible nitric oxide synthase
(iNOS) expression and increased NO bioavailability
(Figure 1) [16-18]. NOX is the major source of ROS
in endothelial and myocardial cells [1,19]. Activation
of NOX leads to the formation of intracellular O2
–. Addi-
tion of ascorbate to endothelial cells exposed to oxidative
stress prevented activation of NOX by inhibition of sub-
unit p47phox expression (mediated by the Jak2/Stat1/
IRF1 signaling pathway) [20]. NOX-derived ROS addi-
tionally increase the expression of iNOS [17], producing
excessive NO. Abundant NO in the presence of O2
– gen-
erates peroxynitrite. Ascorbate prevented iNOS expres-
sion [16]. Ascorbate also scavenges O2
–, but only at high
levels ≥10 mmol/l [21].
Furthermore, ascorbate can increase NO bioavailability
by preventing BH4 oxidation and recovering oxidized
BH4 [18]. Recovery of BH4 by ascorbate prevents un-
coupling of eNOS and associated O2
– production and
restores eNOS activity and subsequent generation of
eNO, which has a pivotal role in endothelial-dependent
vasodilatation.
Endothelial permeability
ROS additionally increase endothelial permeability [22],
causing edema and contributing to organ dysfunction.
Ascorbate can tighten the endothelial barrier through
several pathways.
Constitutive eNO is required to control endothelial per-
meability and prevent loss of tight junctions between cells
[23]. Loading endothelial cells with ascorbate preserved
eNO generation through eNOS and decreased endothelial
permeability. This effect depended on eNOS and guanyla-
tecyclase, suggesting that tightening of the endothelium
involved NO generation by eNOS and subsequent
NO-dependent activation of guanylatecyclase [23].
Exposure of endothelial cells to lipopolysaccharide
(LPS) increases endothelial permeability by inducing
NOX-dependent protein phosphatase 2A activity and
subsequent occludin dephosphorylation. Phosphorylated
occludin is crucial to maintain tight junctions. Ascorbateprotects against vascular leakage by inhibiting protein
phosphatase 2A activation [24].
Furthermore, oxidants and LPS increase apoptosis,
impairing the endothelial barrier. LPS decreases Bcl-2
(which inhibits apoptosis) and increases Bax (which sup-
presses the ability of Bcl2 to block apoptosis). Ascorbate
inhibited apoptosis [25] and protected endothelial progeni-
tor cells [26]. Simultaneous administration with vitamin E
had a synergistic effect on the prevention of apoptosis.Impairment of microcirculatory flow
Oxidative stress stimulates the expression of tissue factors
and cellular adhesion molecules at the surface of platelets
and endothelial cells [27], promoting adhesion of leuco-
cytes to the endothelium and formation of microthrombi
and thus impairing microcirculatory flow. In cultured
endothelial cells, ascorbate inhibited the tumor necrosis
factor alpha-induced expression of intracellular adhesion
molecule-1 in a dose-dependent manner [28], probably by
modulating the production of ROS and reactive nitrogen
species. By preventing intracellular adhesion molecule ex-
pression, ascorbate reduces leukocyte plugging in micro-
vessels and microcirculatory flow impairment.Myocardial effects of vitamin C in ischemia/reperfusion
Ischemia/reperfusion injures not only the endothelium
but also the myocardium, leading to stunning and ar-
rhythmias. Loading isolated cardiomyocytes subjected
to hypoxia/reoxygenation with ascorbate improved
their resistance to cell death by decreasing ROS gen-
eration and inhibiting (proapoptotic) Bax expression,
caspase-3 activation, and cytochrome-c translocation
into the cytoplasm [29]. Pretreatment with vitamin C
or vitamin E of isolated cardiomyocytes exposed to
singlet oxygen reduced the number of hypercontracted
cardiomyocytes in a concentration-dependent manner.
Simultaneous administration of both vitamins acted syner-
gistically [30].Immune effects of vitamin C in sepsis
In sepsis, ascorbate also influences macrophage activity
and bacterial growth. Macrophages play an important
role in sepsis, enhancing cytokine production as well as
production of several types of ROS. ROS are necessary
to overcome infections, but are only beneficial if their
production is controlled. Incubation of macrophages
with ascorbate regulated the phagocytic process by
reducing adherence, chemotaxis, ingestion and O2
– anion
production [31]. Furthermore, ascorbate has profound
bacteriostatic activity. Ascorbate (in concentrations from
100 to 1,000 μM) significantly inhibited bacterial replica-
tion in dilute fecal samples in vitro [32].
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Ischemia/reperfusion
Beneficial effects of ascorbate pretreatment on organ
function were observed in ischemia reperfusion injury
models of rat heart [33] and rabbit kidney [34], and of
rat skeletal muscle [35,36], lung [37] and liver [38-41].
Studies are summarized in Table 1.
In a rat model of cardiac arrest (ventricular fibrillation
and electrical shock), intravenous ascorbate at the start
of resuscitation alleviated postcardiac arrest myocardial
necrosis and mitochondrial damage, reduced lipid per-
oxidation and improved the resuscitation success rate
and 72-hour survival [33]. In a pig model of coronary
artery ischemia/reperfusion and preconditioning, intra-
venous ascorbate started 30 minutes before ischemic
preconditioning or ischemia had no effect on infarct size,
but abolished the reduction in infarct size by ischemic
preconditioning [42]. In a rabbit renal ischemia model,
ascorbate ameliorated renal structure and function [34].
Ascorbate also had a positive effect on muscle injury when
administered intravenously (i.v.) during ischemia/reperfu-
sion of the leg in rats [36]. Experiments with different
intravenous ascorbate doses to rats prior to hepatic
ischemia reperfusion found antioxidant effects at low and
moderate doses and predominant pro-oxidant effects at
extremely high doses (1,000 mg/kg) [38]. In addition, vita-
min C administered after ischemic preconditioning but
before clamping of the liver blood flow reduced hepatic
mitochondrial damage and dysfunction [41]. Thus, in
these animal models, ascorbate reduced ischemic organ
injury and improved function, but abolished the protective
effects of ischemic preconditioning on organ injury.
Sepsis
The most frequently used sepsis animal models are feces
injection into the peritoneum (FIP), cecal ligation and
puncture (CLP) and intraperitoneal injection of LPS.
Ascorbate depletion
Ascorbate plasma concentrations rapidly declined in lym-
phocytes and macrophages [43], muscle [6] and plasma
[32,44] of septic rodents. Endotoxin also depleted myocar-
dial ascorbate in guinea pig hearts after as early as 4 hours,
even after dietary supplementation for 5 weeks [45].
Systemic circulation, microcirculation and permeability
Ascorbate (76 mg/kg i.v.) restored blood pressure and
prevented microvascular dysfunction in skeletal muscle
of septic rats [32]. In a mouse model of FIP, ascorbate
(10 mg/kg i.v.) inhibited impairment of microvascular
perfusion when administered early (0 hours) and reversed
septic platelet adhesion and flow impairment with late
administration (after 6 hours) [46]. Similarly, ascorbate
improved capillary blood flow by an eNOS-dependentmechanism when administered 6 hours after FIP [44,47].
In addition, ascorbate (200 mg/kg i.v.) administration
before CLP protected against impaired arteriolar cons-
triction and loss of catecholamine responsiveness and
improved 24-hour survival in mice [6,48]. Ascorbate
prevented arteriolar vasoconstriction by inhibiting eNOS
uncoupling and iNOS-derived and neuronal nitric oxide
synthase-derived NO production, when given before but
also 3 hours after CLP in mice [48-50]. Moreover, ascor-
bate (200 mg/kg i.v.) prevented vascular leakage in a
mouse CLP model by inhibiting excessive production of
NO by iNOS and neuronal nitric oxide synthase, and of
O2
– by NOX, and by inhibiting the activation of protein
phosphatase 2A, thereby preserving occludin phosphoryl-
ation [50]. Ascorbate thus restored several seemingly
contradictory disorders contributing the heterogeneity of
the septic circulation. Ascorbate improved microcircula-
tory perfusion by NOX inhibition and arteriolar vasodilator
responsiveness (neuronal nitric oxide synthase related), re-
stored vasoconstrictor responsiveness by inhibiting iNOS
expression and prevented vascular leakage.
Effects on organ injury and function
Vitamin C prevented the increase in endotoxin-induced
myocardial uric acid accumulation, a marker of ischemia-
induced oxidative stress [45], and protected against
endotoxin-induced oxidative damage to proteins in the
guinea pig liver [51]. Ascorbate (100 mg/kg i.v.) reduced
hepatic microvascular dysfunction during polymicrobial
sepsis when administered immediately after CLP in rats
by reducing oxidative stress and lipid peroxidation, and
regulating hepatic vasoregulatory gene expression [52,53].
In addition, ascorbate prevented the sepsis-induced
decrease in several cytochrome P450 enzyme activities,
thereby improving drug-metabolizing function [53]. As-
corbate (200 mg/kg i.v.) also attenuated sepsis-induced
acute lung injury in a mouse model of FIP or LPS [54,55]
and improved 72-hour survival [54]. Finally, oral prefeed-
ing with ascorbate decreased bacterial concentrations
and improved survival after intraperitoneal injection
of Klebsiella pneumonia in mice [56].
Role of vitamin C in ischemia/reperfusion and
sepsis: human volunteers
In human volunteers, both ischemia/reperfusion injury
(20 minutes of forearm ischemia) [57] and low-dose LPS
[58] reduced plasma vitamin C concentrations and dimin-
ished acetylcholine-induced, endothelial-dependent vaso-
dilatation. High-dose (24 mg/minute) intra-arterial vitamin
C increased BH4 concentrations [59], reduced neutrophil
oxidative burst and completely restored the response to
acetylcholine, but not to glyceryl-trinitrate (endothelium-
independent dilatation), supporting its endothelial pro-
tective effect. Vitamin C also corrected the LPS-induced
Table 1 Pathophysiological effects and mechanisms of vitamin C in sepsis and ischemia reperfusion: animal studies
Model; dose and timing of ascorbate [study] Pathophysiological effect Mechanisms
Ischemia reperfusion
Cardiac arrest (VF-ES) in rats; 50 and 100 mg/kg
i.v. at start of CPR [33]
Increases successful resuscitation after
cardiac arrest rates and 72-hour survival




(complex I and IV)
Inhibits MDA ↑
LAD coronary artery ischemia ± ischemic
preconditioning in pigs; 2 g i.v. + 25 mg/minute
before IPC or before ischemia [42]
Does not affect infarct size
Attenuates the beneficial effect of ischemic
preconditioning indicating free oxygen
radicals are involved in ischemic preconditioning
Middle cerebral artery clamping in mice; DHA 40,
250 and 500 mg/kg, AA 250 and 500 mg/kg,
before, 15 minutes and 3 hours after [81]
DHA gives dose-dependent: DHA passes blood–brain barrier,
ascorbate does not
● Reperfusion blood flow ↑ No beneficial effect of ascorbate
● Infarct size ↓
● Neurological deficit ↓
● Mortality ↓ (if given before ischemia)
Abdominal aortic clamping in rats; 100 mg/kg
i.v. before [37]
Attenuates lung injury MDA in blood and lung ↓
Renal ischemia in rabbits; 15 mg/kg 24 hours
and 1 hour before and 0.83 mg/minute
during [34]
Ameliorates renal structure and function PAF and PAF-like lipids ↓
Myeloperoxidase activity ↓
Hepatic ischemia (clamping HA–PV) rats; 30,
100, 300, and 1,000 mg/kg 5 minutes
before [38]
Bile flow and cholate secretion ↑ 30 and 100 mg/kg:
Extremely high dose is prooxidant ● AST and lipid peroxidation ↓
● Prevents ↓ of cytochrome
P450 1,000 mg/kg
● Injury and loss of function ↑
IPC + hepatic ischemia (clamping left HA and
PV) in rats; 100 mg/kg i.v. after IPC before
clamping [41]
Ascorbate or IPC plus ascorbate after




● Peroxide ↑, MDA ↑
● GSH and GSH/GSSG ↓
● Glutamate dehydrogenase ↓
● ATP ↓ (ascorbate plus IPC)
Liver ischemia in rats; 100 mg/kg i.v. 1 hour
before [40]
Attenuates reperfusion liver injury Attenuation of O2
– and NO release
Liver ischemia (clamping HA and PV) in rats;
oral vitamin C for 5 days [39]
Attenuates myocardial injury and protects
cardiac function after liver ischemia
Systemic hydroxyl radical ↓
Myocardial MDA
Skeletal muscle ischemia in rats; oral
vitamin C for 5 days [35]
Preserves muscle function Muscle myeloperoxidase ↓
Reduces edema Neutrophil infiltration ↓
Respiratory burst ↓
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Table 1 Pathophysiological effects and mechanisms of vitamin C in sepsis and ischemia reperfusion: animal studies
(Continued)
Skeletal muscle tourniquet in rats; 50 mg/kg
i.v. before ischemia, before reperfusion,
or both [36]
Preserves muscle function Blood malondialdehyde↓




CLP in rats; 76 mg/kg i.v. directly after [32] Restores blood pressure and density
of perfused capillaries
CLP in mice; 200 mg/kg 30 minutes
before [6]
Improves microvascular constriction





CLP in mice; baseline and 23 hours
after 200 mg/kg [48]
Restores arteriolar conducted vasoconstriction Reduces increased:
● nNOS activity
● Nitrite/nitrate
CLP in rats; 76 mg/kg after 1 hour,
6 hours and 2 hours [44]
Prevents maldistributed blood flow
and low arterial blood pressure
Blood flow impairment:
● Requires NADPH oxidase
● Reversal by ascorbate or BH4
● eNOS dependent
FIP in mice; 10 or 200 mg/kg i.v.
6 hours after [47]
Prevents/reverses septic impairment of
capillary blood flow for 18 hours and
improves survival
Blood flow impairment depends
on the NADPH oxidase subunit
gp91phox
Ascorbate effects are eNOS dependent
Ascorbate suppresses iNOS ↑ activity
FIP in mice; 10 mg/kg i.v. prophylactic
or delayed [46]
Prevention or reversal of septic platelet
adhesion and/or flow stoppage
Capillary flow stoppage
● eNOS dependent
● Platelet adhesion predicts 90 %
CLP in mice; 200 mg/kg i.v. at baseline
and 3 hours after [50]
Prevents vascular leakage Inhibits production of:
● O2
– and NO by NADPH oxidase,
iNOS and nNOS
● Peroxynitrite
● 3-Nitrotyrosine-positive proteins ↓
● Inhibits PP2A activation
Preserves endothelial occludin
phosphorylation
Organ injury and function
Intraperitoneal LPS in guinea pigs;
low vs. high vitamin C diet [51]
Dietary vitamin C Hepatic lipid peroxidation ↓
Increases hepatic vitamin C and vitamin E
content
Hepatic protein carbonyls ↓
Reduces oxidative damage to lipids and proteins Hepatic GSH and GSH/GSSG ↑
(vitamin C + vitamin E)
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Table 1 Pathophysiological effects and mechanisms of vitamin C in sepsis and ischemia reperfusion: animal studies
(Continued)
CLP in rats; 100 mg/kg directly after [53] Decreases hepatic injury Suppresses AST and ALT ↑
Improves drug-metabolizing function Prevents GSH and GSH/GSSG ↓
Prevents CYP1A1 and CYP2E1 mRNA,
and CYP1A2 activity
FIP or LPS in mice; 200 mg/kg i.p.
after LPS [54]
Attenuates sepsis-induced acute lung
injury and improves 72-h survival
Preserves lung architecture and barrier
Proinflammatory chemokine expression ↓
microvascular thrombosis ↓
Nuclear factor-kappaB activation ↓
Normalizes coagulation
Immune defense against infection
Klebsiella pneumonia in mice; ascorbate
deficient vs. ascorbate supplemented
for 25 days [56]




● Amino acid and lipid peroxidation
Higher concentration of bacteria in
ascorbate deficiency
AA, ascorbic acid; ALT, alanine aminotransferase; AST, aminotransferase; BH4, tetrahydrobiopterin; CLP, cecal ligation and perforation; CPR, cardiopulmonary
resuscitation; CYP, cytochrome P450; DHA, dehydroascorbic acid; eNOS, endothelial nitric oxide synthase; ES, electrical shock; FIP, feces injection into the
peritoneum; GSH, reduced glutathion; GSSG, glutathione disulphide; HA, hepatic artery; IPC, ischemic preconditioning; LAD, left anterior descending; LPS,
lipopolysaccharide; MDA, malondialdehyde (marker for lipid peroxidation); iNOS, inducible nitric oxide synthase; i.p., intraperitoneal; i.v., intravenous; NADPH,
nicotinamide adenine dinucleotide phosphate; nNOS, neuronal nitric oxide synthase; NO, nitric oxide; O2
–, superoxide; PAF, platelet-activating factor; PPA2, protein
phosphatase 2A; PV, portal vein; ROS, reactive oxygen species; VF, ventricular fibrillation. ↑, increase; ↓, decrease; =, constant.
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sin II [60]. Both vasopressors act independent of the endo-
thelium, but their effect is blunted by oxidative stress and
inflammation. These volunteer studies originate from the
same group.
Several preclinical in vitro, animal and volunteer stud-
ies thus show that vitamin C in moderate to high doses
can reduce ROS-induced microcirculatory flow impair-
ment, microvascular leakage, decreased responsiveness
to vasoconstrictors, and myocardial and other organ in-
jury. Contradictory results in ischemia/reperfusion can
partially be explained by the timing of administration,
because vitamin C abrogates ischemic preconditioning.
Furthermore, vitamin C reduces the overwhelming neu-
trophil response and inhibits bacterial replication.
Plasma concentrations, dose and
pharmacokinetics of vitamin C: patients
Plasma concentrations
Vitamin C plasma concentrations depend on absorption,
the distribution volume, cellular uptake, consumption
and renal reabsorption and excretion. Patients with
sepsis, hemorrhage, multiple organ failure, stroke,
traumatic brain injury or after cardiac surgery have
low vitamin C concentrations in plasma [61-68] and leu-
kocytes [69], probably due to increased consumption
in the cell [70] and high leukocyte turnover. Sinceintracellular ascorbate concentrations in mononuclear
leucocytes and in granulocytes are respectively 80 and
25 times higher than in plasma [71], a high production
and turnover of these cells contributes to depletion. Low
plasma concentrations correlate with inflammation (C-re-
active protein) [64] and multiple organ failure [55], sug-
gesting consumption during oxidative stress.
Dosing
Recommended doses of vitamins are generally based on
preventing deficiency in healthy humans. In healthy vol-
unteers, manifestations of vitamin C deficiency (fatigue
and/or irritability) occurred at plasma concentrations
below 20 μmol/l. Clear scurvy can develop below 11 μmol/l
[13]. With sufficient vitamin C intake (100 to 300 mg/day),
plasma concentrations plateau at 70 to 85 μmol/l and do
not exceed 220 μmol/l at maximal oral intake (3 g six times
daily) [72]. Oral dose is limited by intestinal absorption and
high oral intake causes diarrhea [73]. Urinary excretion
depends on the plasma concentration and is minimal at
low plasma concentrations due to active tubular reabsorp-
tion [74,75]. Threshold plasma concentration for excretion
may be 55 μmol/l [72].
Ascorbate is transported into the cell by ascorbate-
specific membrane transporters and less so as dehydroas-
corbic acid via glucose transporters [76]. Within the cell,
dehydroascorbic acid can be rapidly reduced to ascorbate,
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ter SVCT1 is expressed predominantly in epithelial tissues
such as the intestine and kidney, maintaining optimal
vitamin C concentrations in the body. The ascorbate
transporter SVCT2 delivers ascorbic acid to tissues [78].
Immune and inflammatory cells have intracellular concen-
trations 10 to 80 times higher than plasma, protecting
them against ROS generated by respiratory burst or
phagocytosis [71]. Neurons have concentrations as high as
10 mmol/l, sufficient for scavenging O2
– [79,80]. Of note,
ascorbate does not pass the blood–brain barrier. However,
dehydroascorbic acid does so via the glucose transporter
GLUT1 and is reduced to ascorbate after uptake in neu-
rons. Intravenous administration of dehydroascorbic acid
confers supraphysiologic concentrations of ascorbate in
the brain [81].
Notably, concentrations attained with high oral dosing
are sufficient to modulate enzymes such as nicotinamide
adenine dinucleotide phosphate but not for scavenging
O2
–, which reacts with NO at a rate 105-fold greater than
that with ascorbate [21]. A plasma concentration of
10 mmol/l would be required to compete with NO and
for complete restoration of NO bioavailability. High
plasma concentrations can be obtained with intravenous
administration. However, mild dietary supplementation
of vitamin C reduced peroxynitrite formation and atrial
electrophysiological remodeling induced by rapid pacing
in dogs [82], probably due to higher intracellular vitamin
C concentration.
High intravenous vitamin C doses, up to 3 to 6 g daily,
are needed to restore normal plasma concentrations in
critically ill patients [83]. To attain plasma concentra-
tions over 10 mmol/l for 3 hours, a short-term infusion
of 30 to 100 g would be required [73,74]. High pharma-
cological doses of vitamin C seem to be well tolerated
[84,85]. Prolonged oral intake of high-dose vitamin C
increases the risk of oxalate kidney stones [86]. However,
this complication has not been reported with short-term
high intravenous dosing [87]. Of note, low dose ascor-
bate can also act as a pro-oxidant [37]. However, after a
1 g vitamin C intravenous infusion, ascorbyl radical con-
centrations increased much more in healthy controls
than in septic patients, who had a lower baseline con-
centration [88].
Role of vitamin C in ischemia/reperfusion: clinical
studies
Whereas most preclinical studies investigate the role of
vitamin C alone, clinical studies often used a combination
of antioxidants. Some studies are performed in conditions
similar to animal models, reporting the use of vitamin C
before the ischemic incident (coronary bypass surgery) or
directly at reperfusion (percutaneous coronary interven-
tions) or shock resuscitation (burns). In the critically illstudies, combinations of antioxidants were generally given
after the hyperacute phase.
Percutaneous coronary intervention
In patients undergoing elective percutaneous coronary
intervention, vitamin C in a dose of 1 g over 1 hour im-
proved microcirculatory reperfusion, and left ventricular
and renal function [89]. This improvement was associ-
ated with reduced markers of oxidative injury.
Cardiac surgery
Atrial fibrillation is the most common arrhythmia after
cardiac surgery, developing in 15 to 50 % of patients
depending on several risk factors [90]. Atrial fibrilla-
tion increases short-term and long-term morbidity
and length of hospital stay [90,91], and necessitates
anticoagulation to prevent stroke. Its pathogenesis is
multimodal but accumulating evidence indicates a
role of oxidative stress [92-94]. Ischemia/reperfusion,
atrial stress and angiotensin increase atrial NOX activity,
which is associated with postoperative atrial fibrillation
[94-96]. Oxidative damage initiates breakdown of cell
membranes, mitochondrial dysfunction, calcium overload,
apoptosis and also inflammation by signaling activation of
nuclear factor-kappaB and activator protein-1 transcrip-
tion factors [97], thereby initiating electrophysiological
remodeling.
After cardiac surgery, a massive depletion of vitamin C
has been observed [66]. Several studies suggest a benefi-
cial effect of vitamin C on the occurrence of new atrial
fibrillation and some on enhanced recovery, although
not all studies are positive (Table 2). In a matched con-
trol study, the perioperative use of vitamin C reduced
the incidence of new postoperative atrial fibrillation in
patients undergoing coronary artery bypass grafting [82].
A subsequent randomized controlled trial found a reduc-
tion in postoperative atrial fibrillation when adding vita-
min C to a β-blocker [98]. In the largest trial, vitamin C
did not reduce atrial fibrillation, but it reduced time on
mechanical ventilation [99]. Another clinical trial found a
reduction in atrial fibrillation, but its incidence in the
control group was extremely high [100]. The most re-
cent randomized controlled trial found a reduction in
postoperative atrial fibrillation comparing preoperative
ω-3 poly-unsaturated fatty acids with vitamin C and
vitamin E supplementation with placebo (see Table 2)
[95]. An older Chinese study using a very high dose
of intravenous vitamin C (250 mg/kg) found less cardiac
injury, better cardiac performance and shorter intensive
care and hospital stay [101].
Studies differ in the timing, route and dose of vita-
min C, and in the combination of other antioxidants.
Timing may be crucial in cardiac surgery, because
preoperative episodes of ischemia and reperfusion protect
Table 2 Controlled studies on the effect of vitamin C in cardiac surgery patients











i.v. vitamin C; 250 mg/kg
i.v. before
45 MDA ↓; CK, CK-MB ↓; postbypass
defibrillation 0 vs. 12.5 %; CI ↑,






Oral vitamin C; 2 g night
before, 500 mg daily for
5 days
43 16.3 0.048
Matched control 43 34.9
Eslami and
colleagues [98]
RCT; CABG β-Blocker + oral vitamin C;
2 g night before, 1 g
twice daily for 5 days
50 4 0.002
β-Blocker alone 50 26
Bjordahl and
colleagues [99]
RCT; CABG Oral vitamin C; 2 g night
before, 1 g twice daily for
5 days
89 30.3 0.985 Shorter time on ventilator,




RCT; CABG i.v. vitamin C; 2 g 3 hours
before CPB
85 44.7 0.041 Time to SR conversion ↓,
LOS hospital ↓, LOS ICU ↓
i.v. saline 85 61.2
Rodrigo and
colleagues [95]
RCT Preoperative PUFA; 2 g/day
for 5 days; vitamin C 1 g/day +
vitamin E 400 IU/day for
2 days preoperatively and
postoperatively until discharge
103 9.7 <0.001 Oxidative stress-related
biomarkers in atrial tissue ↓
Placeboa 100 32
CABG, coronary artery bypass surgery; CI, cardiac index; CK, creatinine phophokinase; CK-MB, creatinine phosphokinase muscle, brain isoenzyme; CPB, cardiopulmonary
bypass; i.v., intravenously; LOS, length of stay; MDA, malondialdehyde; POAF, postoperative atrial fibrillation; PUFA, ω-3 polu-unsaturated fatty acids containing
eicosapentaenoic and docosahexaenoic acids in a 1:2 ratio; RCT, randomized controlled trial; SR, sinus rhythm; ↑, increase; ↓, decrease; =, constant. aPlacebo contained
500 mg inert microgranules, 825 mg triglycerides and 500 mg vegetable oil per capsule.
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and vitamin C may hamper the beneficial effects of ische-
mic preconditioning on reducing infarct size [102].
Critically ill patients
Several clinical trials in critically ill patients have re-
ported favorable results of high-dose vitamin C alone
[90,91], or in combination with vitamin E [103,104] or
with selenium, zinc and vitamin B [105,106] (Table 3).
The main beneficial outcomes include reduction in pul-
monary morbidity and new organ failure, less mechan-
ical ventilation days and shorter length of ICU and/or
hospital stay. Some studies measured lower markers of
oxidative stress [84,107]. Although ROS can signal host
defense in low concentrations, the parallel finding of less
oxidant stress and less organ dysfunction suggests a
beneficial effect of reducing overwhelming ROS during
critical illness. The largest study, however, using a mixture
of micronutrients including oral vitamin C, found no effect
on 28-day mortality or length of stay. Of note, the control
group in Berger and colleagues’ study received 500 mg/day
vitamin C [105].Combined administration with vitamin E and other
micronutrients obscures the role of vitamin C. However,
vitamin C regenerates vitamin E, and vitamin E is only
consumed after depletion of vitamin C [108]. Two
small studies in burn patients studied a very high dose of
vitamin C alone (66 mg/kg/hour) for about 24 hours and
found a reduction in resuscitation volume, better gas
exchange and less days on mechanical ventilation [84]
and increased urinary output [85], probably indicating less
capillary leak. No signs of acidosis or renal insufficiency
were found with this high dose. However, although vita-
min C reduced morbidity in some studies, a mortality
reduction was not found. We hypothesize that the effect
of vitamin C can be improved by very early administration
of a high intravenous dose as part of the resuscitation
bundle in patients with shock.
Conclusion
This narrative review summarizes the role of vitamin C
in mitigating ROS-induced microcirculatory impairment
and associated organ failure in ischemia/reperfusion or
sepsis. Preclinical studies show that high-dose vitamin C
Table 3 Controlled studies on the effect of vitamin C in critically ill patients





RCT; trauma and MOF i.v. vitamin C 1 g three times daily;
enteral vitamin E 1,000 IU three times daily
301 Pulmonary morbidity ↓, new MOF ↓,
LOS ventilation ↓, LOS ICU ↓
With TPN, vitamin C 100 mg and vitamin E
10 IU daily; with EN, vitamin C 340 mg/l,




RCT; critically ill (mainly
trauma, cardiogenic shock)
Vitamin C 500 mg/day and vitamin E
(400 IU/day) in EN
105 Ventilator-free days ↓, 28-day mortality ↓





i.v. or oral vitamin C 1 g three times
daily + oral vitamin E 1,000 IU three times
daily + selenium 200 μg i.v.
2,272 LOS ICU ↓, LOS hospital ↓, mortality ↓;






Selenium 540 i.v. day 1, 270 μg days 2 to 5;
zinc 60 mg i.v. day 1, 30 mg days 2 to 5;
vitamin B1 305 mg i.v. day 1, 205 mg days
2 to 5; vitamin C 2.7 g i.v. day 1, 1.6 g days
2 to 5; vitamin E 600 mg i.v. day 1,
300 mg
days 2 to 5
102 New organ failure ND, new infections
ND, LOS shorter in trauma, CRP ↓ in
cardiac surgery and trauma, recovery
of health after discharge ↑
Vitamin B1 100 mg i.v. days 1 to 3
(both groups); vitamin C 500 mg i.v.




RCT, 2 × 2 factorial; critically
ill adults with multiple
organ failure
Selenium 500 μg i.v., selenium 300 μg
or zinc 20 mg or β-carotene 10 mg;
vitamin E 500 mg or vitamin C 1,500 mg
307 No difference in 28-day mortality




RCT; severe burn <2 hours Ringer lactate + 66 mg/kg/hour vitamin C 19 Fluid requirements ↓, body weight
gain ↓, PF ratio ↑, days on mechanical
ventilation ↓





Ringer lacate + 66 mg/kg/hour vitamin C 17 Fluid requirements ↓, urinary output ↑
Ringer lactate for 24 hours 16
CI, confidence interval; CRP, C-reactive protein; EN, enteral nutrition; i.v., intravenously; LOS, length of stay; OR, odds ratio; MOF, multiple organ failure; ND, no
difference; PF, ratio of partial oxygen pressure in arterial blood to fraction of inspired oxygen; RCT, randomized controlled trial; TPN, total parenteral nutrition; SAB,
subarachnoid bleeding. ↑, increase; ↓, decrease; =, constant.
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flow impairment, prevent or restore vascular responsive-
ness to vasoconstrictors, preserve endothelial barrier and
augment antibacterial defense. These protective effects
against oxidative stress seem to mitigate organ injury and
dysfunction, and promote recovery in most but not all
clinical studies after cardiac revascularization and in critic-
ally ill patients.
Of note, many questions remain to be solved, includ-
ing the optimal dose, timing, combination of vitamin C
with other antioxidants and the inhibiting effect of vita-
min C on the protection of ischemic preconditioning.
However, high-dose vitamin C provides a cheap, strong
and multifaceted antioxidant. Future research should
answer the question of whether short-term high-doseintravenous vitamin C can mitigate the overwhelming
oxidant cascade and thereby improve resuscitation of
the macrocirculation and microcirculation and limit
cellular injury in critically ill patients.
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